Fecal transplantation for treatment of inflammatory bowel disease.
CONCLUSIONS: Fecal microbiota transplantation may increase the proportion of participants achieving clinical remission in UC. However, the number of identified studies was small and the quality of evidence was low. There is uncertainty about the rate of serious adverse events. As a result, no solid conclusions can be drawn at this time. Additional high-quality studies are needed to further define the optimal parameters of FMT in terms of route, frequency, volume, preparation, type of donor and the type and disease severity. No studies assessed efficacy of FMT for induction of remission in CD or in pediatric participants. In addition, no studies assessed long-term maintenance of remission in UC or CD. Future studies are needed to address the therapeutic benefit of FMT in CD and the long-term FMT-mediated maintenance of remission in UC or CD.
PMID: 30480772 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Imdad A, Nicholson MR, Tanner-Smith EE, Zackular JP, Gomez-Duarte OG, Beaulieu DB, Acra S Tags: Cochrane Database Syst Rev Source Type: research
More News: Australia Health | Canada Health | Chronic Pain | Clostridium Difficile | Conferences | Crohn's Disease | Cytomegalovirus | Databases & Libraries | Gastroenterology | General Medicine | Genetics | Headache | Inflammatory Bowel Disease | Laboratory Medicine | Netherlands Health | Pain | Pediatrics | Pneumonia | Respiratory Medicine | Study | Transplants | Ulcerative Colitis | Upper Endoscopy